000916868 001__ 916868
000916868 005__ 20230224084246.0
000916868 0247_ $$2doi$$a10.1002/mds.29172
000916868 0247_ $$2ISSN$$a0885-3185
000916868 0247_ $$2ISSN$$a1531-8257
000916868 0247_ $$2Handle$$a2128/33573
000916868 0247_ $$2pmid$$a35943058
000916868 0247_ $$2WOS$$aWOS:000837651900001
000916868 037__ $$aFZJ-2023-00160
000916868 082__ $$a610
000916868 1001_ $$0P:(DE-HGF)0$$aBanwinkler, Magdalena$$b0
000916868 245__ $$aGray Matter Volume Loss in Proposed Brain‐First and Body‐First Parkinson's Disease Subtypes
000916868 260__ $$aNew York, NY$$bWiley$$c2022
000916868 3367_ $$2DRIVER$$aarticle
000916868 3367_ $$2DataCite$$aOutput Types/Journal article
000916868 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1673610071_32709
000916868 3367_ $$2BibTeX$$aARTICLE
000916868 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000916868 3367_ $$00$$2EndNote$$aJournal Article
000916868 520__ $$aBackground: α-Synuclein pathology is associated with neuronal degeneration in Parkinson's disease (PD) and considered to sequentially spread across the brain (Braak stages). According to a new hypothesis of distinct α-synuclein spreading directions based on the initial site of pathology, the "brain-first" spreading subtype would be associated with a more asymmetric cerebral and nigrostriatal pathology than the "body-first" subtype.Objective: Here, we tested if proposed markers of brain-first PD (ie, higher dopamine transporter [DaT] asymmetry; absence of rapid eye movement sleep behavior disorder [RBD]) are associated with a greater or more asymmetric reduction in gray matter volume (GMV) in comparison to body-first PD.Methods: Data of 255 de novo PD patients and 110 healthy controls (HCs) were retrieved from the Parkinson's Progression Markers Initiative. Structural magnetic resonance images were preprocessed, and GMVs and their hemispherical asymmetry were obtained for each of the neuropathologically defined Braak stages. Group and correlation comparisons were performed to assess differences in GMV and GMV asymmetry between PD subtypes.Results: PD patients demonstrated significantly smaller bilateral GMVs compared to HCs, in a pattern denoting stage-dependent disease-related brain atrophy. However, the degree of putaminal DaT asymmetry was not associated with reduced GMV or higher GMV asymmetry. Furthermore, RBD-negative and RBD-positive patients did not demonstrate a significant difference in GMV or GMV asymmetry.Conclusions: Our findings suggest that putative brain-first and body-first patients do not present diverging brain atrophy patterns. Although certainly not disproving the brain-first/body-first spreading hypothesis, this study fails to provide evidence in support of it. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.Keywords: dopamine transporter; rapid eye movement sleep; rapid eye movement sleep behavior disorder; α-synuclein spread.
000916868 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000916868 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x1
000916868 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000916868 7001_ $$0P:(DE-HGF)0$$aDzialas, Verena$$b1
000916868 7001_ $$0P:(DE-Juel1)178642$$aHoenig, Merle C.$$b2
000916868 7001_ $$0P:(DE-Juel1)169110$$avan Eimeren, Thilo$$b3$$eCorresponding author
000916868 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.29172$$gVol. 37, no. 10, p. 2066 - 2074$$n10$$p2066 - 2074$$tMovement disorders$$v37$$x0885-3185$$y2022
000916868 8564_ $$uhttps://juser.fz-juelich.de/record/916868/files/Movement%20Disorders%20-%202022%20-%20Banwinkler%20-%20Gray%20Matter%20Volume%20Loss%20in%20Proposed%20Brain%E2%80%90First%20and%20Body%E2%80%90First%20Parkinson%20s%20Disease.pdf$$yOpenAccess
000916868 909CO $$ooai:juser.fz-juelich.de:916868$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000916868 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)178642$$aForschungszentrum Jülich$$b2$$kFZJ
000916868 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000916868 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x1
000916868 9141_ $$y2022
000916868 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-11
000916868 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-11
000916868 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-11
000916868 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000916868 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-11
000916868 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2021$$d2022-11-11
000916868 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2022-11-11$$wger
000916868 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-11
000916868 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-11
000916868 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000916868 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-11
000916868 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2021$$d2022-11-11
000916868 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-11
000916868 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-11
000916868 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-11$$wger
000916868 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-11
000916868 920__ $$lyes
000916868 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
000916868 980__ $$ajournal
000916868 980__ $$aVDB
000916868 980__ $$aUNRESTRICTED
000916868 980__ $$aI:(DE-Juel1)INM-2-20090406
000916868 9801_ $$aFullTexts